Oxford University and Vaccitech Welcome UK Regulatory Emergency Use Authorisation of Coronavirus Vaccine

Total Page:16

File Type:pdf, Size:1020Kb

Oxford University and Vaccitech Welcome UK Regulatory Emergency Use Authorisation of Coronavirus Vaccine Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine December 30, 2020 Oxford, UK – Vaccitech Ltd announces that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The vaccine was co-invented by Vaccitech and The University of Oxford’s Jenner Institute. The Joint Committee on Vaccination and Immunisation (JCVI) will also publish its latest advice for the priority groups to receive this vaccine, with this announcement indicating that the JCVI has advised the priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible. The second dose completes the course and is important for longer term protection, and everyone will still receive their second dose within 12 weeks of their first, an approach the JCVI believes will maximise the maximise the benefits of this vaccine, ensuring at-risk people are able to get meaningful protection and ease the pressure on the UK National Health Service. Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: ‘The regulator’s assessment that this is a safe and effective vaccine is a landmark moment, and an endorsement of the huge effort from a devoted international team of researchers and our dedicated trial participants.’ ‘Though this is just the beginning, we will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere, as many as possible as soon possible.’ Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said: ‘This is a day for the team developing the vaccine to celebrate, after a year of extremely hard work under difficult circumstances. Now that the first authorisation or use of the vaccine outside of clinical trials has been granted, we still have more to do and will continue to provide more data to multiple regulatory authorities, until we are able to see the vaccine being used to save lives around the world.’ Professor Adrian Hill, Director of the Jenner Institute said: ‘For the past 25 years, staff at the Jenner Institute have worked to develop vaccines using novel technologies to protect people around the world from diseases that claim many lives each year. The work on ChAdOx1 nCoV-19 builds on many years of research by a dedicated team of vaccinologists, and we are delighted to see the first emergency use licensure.’ The Oxford vaccine (ChAdOx1 nCoV-19) is made from a weakened version of a common cold virus (adenovirus), that has been genetically changed so that it is safe and impossible for it to grow in humans. It is stable, easily manufactured, transported and stored at domestic fridge temperature (2-8 degrees C), so can be easily administered in existing healthcare settings, allowing for the vaccine to be deployed very rapidly. Oxford University’s collaboration with AstraZeneca has been crucial to the successful development of the vaccine and vital for its global manufacturing and distribution across the world. AstraZeneca already has international agreements in place to supply three billion doses of the vaccine, with access being built through more than 30 supply agreements and partner networks. A key element of Oxford’s partnership with AstraZeneca is the joint commitment to provide the vaccine on a not-for-profit basis for the duration of the pandemic across the world, and in perpetuity to low- and middle-income countries. Professor Louise Richardson, Vice-Chancellor at the University of Oxford, said: ‘This is a great day for British science and a great day for universities everywhere. Above all, it is a great day for the many people whose lives will be saved by this vaccine. We are greatly indebted to those who have designed, developed, manufactured and evaluated ChAdOx1.’ Pascal Soriot, Chief Executive Officer, said: ‘Today is an important day for millions of people in the UK who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit. We would like to thank our many colleagues at AstraZeneca, Oxford University, the UK government and the tens of thousands of clinical trial participants.’ Bill Enright, Vaccitech CEO, said: “The UK emergency authorisation of this vaccine is another significant step toward finally controlling the COVID-19 pandemic. The teams at the University of Oxford and AstraZeneca should be applauded for this important work. As co-inventor of the vaccine and the leading developer of the underlying ChAdOx technology for other infectious diseases and cancer, we are extremely pleased by the news.” Vaccitech Media contacts: Katja Stout, Scius Communications (EU) Direct: +44 (0) 7789435990 Email: [email protected] Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc. 212-213-0006 ext. 315 / 364 Email: [email protected] / [email protected] Henry Hodge, Vaccitech Direct: +44 (0) 7533 421 442 Email: [email protected].
Recommended publications
  • The 6-In-1 Vaccine Study
    Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Telephone: 01865 611400 [email protected] www.ovg.ox.ac.uk The 6-in-1 vaccine study Study Information Booklet We are inviting infants aged 8-13 weeks of age to take part in a study comparing two licensed combination vaccines that can be given in the routine UK immunisation schedule. These vaccines protect against 6 different infections in the one injection. Before you decide to take part in this study, it is important for you to understand what the study is about and what participation would involve. Please take time to read the information carefully, and discuss with others if you wish. If you have any questions please contact the study team. Thank you for taking the time to consider this study. Contact the local study team at: Oxford Vaccine Group CCVTM, Churchill Hospital, Oxford, OX3 7LE 01865 611400 [email protected] www.ovg.ox.ac.uk/recruiting-studies Page 1 of 11 The 6-in-1 vaccine study; OVG 2018/05; Participant Information Booklet; REC Ref: 19/SC/0052; IRAS ID: 252324; Version 2.0 dated 23-APR-2019 Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Telephone: 01865 611400 [email protected] www.ovg.ox.ac.uk Summary • This study will help us to better understand the interaction between ‘6- in-1’ vaccines and the Meningococcal B vaccine in the routine UK immunisation schedule • We will be enrolling 240 healthy babies aged 8 – 13 weeks into this study • Babies will receive all their infant immunisations in their own home or in a convenient location until 12 months of age • There will be six study visits including 4 vaccine visits and 2 visits for blood sampling (we will use a topical anaesthetic cream to numb the skin for blood sampling) Why has my child been invited to take part? You have been approached as your child is in the age range for this study and lives in the Thames Valley.
    [Show full text]
  • Chadox1 Ncov-19 Vaccine Prevents SARS-Cov-2 Pneumonia in Rhesus Macaques
    Article ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques https://doi.org/10.1038/s41586-020-2608-y Neeltje van Doremalen1,4, Teresa Lambe2,4, Alexandra Spencer2, Sandra Belij-Rammerstorfer2, Jyothi N. Purushotham1,2, Julia R. Port1, Victoria A. Avanzato1, Trenton Bushmaker1, Received: 13 May 2020 Amy Flaxman2, Marta Ulaszewska2, Friederike Feldmann3, Elizabeth R. Allen2, Hannah Sharpe2, Accepted: 24 July 2020 Jonathan Schulz1, Myndi Holbrook1, Atsushi Okumura1, Kimberly Meade-White1, Lizzette Pérez-Pérez1, Nick J. Edwards2, Daniel Wright2, Cameron Bissett2, Ciaran Gilbride2, Published online: 30 July 2020 Brandi N. Williamson1, Rebecca Rosenke3, Dan Long3, Alka Ishwarbhai2, Reshma Kailath2, Check for updates Louisa Rose2, Susan Morris2, Claire Powers2, Jamie Lovaglio3, Patrick W. Hanley3, Dana Scott3, Greg Saturday3, Emmie de Wit1, Sarah C. Gilbert2,5 ✉ & Vincent J. Munster1,5 ✉ Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic3. Vaccines are an essential countermeasure and are urgently needed to control the pandemic4. Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS-CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profling of the IgG subclass and the expression of cytokines. Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime–boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques.
    [Show full text]
  • CISTM14 Program Schedule
    CISTM14 Program Schedule All sessions held in the Centre des Congrès de Québec. Time Program Location Sunday, 24 May 2015 13.00-17.00 Pre CISTM Course 303AB Pediatric Travel Medicine: what we know, what we think we know and what we actually end up doing! Pre CISTM Course 302AB Expatriates and Lethal Health Threats - Planning, Preparation and Support Learning from Ebola Pre CISTM Course 301AB A Focused Review of Some Topics in Travel Health for Pharmacists 16.00-17.00 Nurses’ Reception Foyer 2 16.00-17.00 Pharmacists’ Reception Foyer 3 17.00-18.20 Opening Ceremony 200ABC 18.00-20.30 Welcome Reception Exhibition 1 Time Program Location Monday, 25 May 2015 MTH1 Meet The History 301AB 8.00-8.45 History of the Quarantine Station at Grosse Ile Marc Desmeules, Canada 8.00-8.45 CDC Yellow Book 302AB Gary Brunette, United States of America COD1 Case of the Day 303AB 8.00-8.45 Pre-Travel Rogelio Lopez-Velez, Spain PL1 Plenary 200ABC 9.00-10.30 Our Shrinking World: Health in the 21st Century Chairs: David R. Shlim, United States of America Leo Visser, The Netherlands PL1.01 Measuring global health: The global is local [Change your mindset! It’s time for a reality check] Louis Loutan, Switzerland • Outline the most important trends and health challenges in the world using gapminder/health metrics • Appraise how these changes (global health transitions, global population growth, urbanization, changes in animal helath and human-animal population interactions, and climate change) will influence global migration and travel medicine now and in the future • Integrate global health concepts into thinking about travel medicine 2 Time Program Location Monday, 25 May 2015, continued Cont.
    [Show full text]
  • Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
    Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020.
    [Show full text]
  • Intrinsic Features in Spinouts UK
    ISSUE 27 Quarterly Journal - June 2018 NEWS COMMENT and ANALYSIS on SPINOUTS from UK HEIs Measuring what is important TEF, REF, then KEF – university staff are used to dealing with Government TLAs and the administration that they entail, and the KEF (Knowledge Exchange Frame- work) brings this activity into the space covered by Spinouts UK. We are well aware that our focus on spinouts and start-ups is only one part of the picture; indeed, as stressed by the report by the MacMillan group in September 2016 on ‘University Knowledge Exchange (KE) Framework: good practice in technology transfer’, “the processes of exploiting university intellectual property through spinning out companies or licensing . is only one route to impact from the many being examined in the knowledge exchange (KE) framework.” The development of the KEF was discussed in detail at the PraxisAuril conference in May, and some of the concerns and questions of the technology transfer and commercialisation professionals in the audience given a full airing. The KEF is due to be rolled out from late autumn onwards, but this timescale means that the first KEF will be restricted to existing data, with other data capture part of an ongoing process. As Tamsin Mann, Head of Policy at PraxisAuril, noted in a blog about the conference discussion, “Evidence underpinning the KEF needs to be challenging and not just measure ‘the good stuff’. There is a clear desire, from PraxisAuril members at least, to capture the quality of engagement and not just the quantities.” Clarity is required, as the KEF is developed, on who it is for and the kind of feedback needed as outputs, and what the KEF can help institutions to do that is not possible with current arrangements.
    [Show full text]
  • Download a PDF of Our Community Brochure
    Engagement with the communities of Oxford and Oxfordshire Did you know? St Giles’ Fair began as the parish feast of St Giles, first recorded in 1624. From the 1780s it became a toy fair, with general amusements for children. In the next century its focus shifted towards adults, with entertainment, rides and stalls. In the late 1800s there were calls for the fair to be stopped on the grounds that it encouraged rowdy behaviour. During Victorian times engineering advances brought the forerunners of today’s rides. Today the huge pieces of machinery fill St Giles’ with sparkling lights for a few days each year, and whizz within feet of ancient college buildings. The stone heads around the Sheldonian Theatre now number thirteen (there were originally fourteen, but one was removed to make way for the adjoining Clarendon Building.) It is not known what they were intended to represent – they might be gods, wise men, emperors or just boundary markers. The original heads were made by William Byrd and put up in 1669. Did you Replacements put up in 1868 were made in poor stone, know? which crumbled away; in 1972 the current set, carved by Michael Black of Oxford, were erected. More on page 4 STARGAZING AND SPIN-OUTS PAGE 1 Contents 2 Introduction from the Vice-Chancellor 3 Foreword from the Chair of the Community Engagement Group 5 Part 1: Part of the fabric of the city Part of the fabric 6 800 years of history of the 8 Economic impact city 9 Science Parks 1 0 Saïd Business School 11 Oxford University Press PART 1 PART 1 2 The built environment 13
    [Show full text]
  • RCN International Nursing Research Conference 2017
    RCN International Nursing Research Conference 2017 Wednesday 5 – Friday 7 April 2017 University of Oxford Examination Schools, 75-81 High Street, Oxford, OX1 4BG, UK Conference abstracts media partner Accrue up to 27 hours #research2017 of CPD Contents Keynote speaker abstracts 4 Concurrent session 6 54 Thursday 6 April 2017 2-2.55pm 54 Theme: Focus groups .................................54 Concurrent session 1 6 Theme: Mixed ........................................55 Wednesday 5 April 2017 11.30am-12.55pm 6 Theme: Qualitative approaches/patient safety and experience .....................................56 Theme: Qualitative approaches ..........................6 Theme: Qualitative approaches/interviews ...............57 Theme: Qualitative approaches .......................... 7 Theme: Evidence review ...............................58 Theme: Qualitative approaches ..........................8 Theme: Qualitative approaches/text and discourse ........59 Theme: Evidence review/patient safety ..................10 Theme: Questionnaires/other methods ..................60 Theme: Mixed eHealth .................................11 Theme: Research methodology ......................... 13 Concurrent session 7 62 Theme: Mixed methods/patient experience ............... 14 Friday 7 April 2017 9.50-10.45am 62 Concurrent session 2 17 Theme: Workforce/review .............................62 Wednesday 5 April 2017 1.55-3.20pm 17 Theme: Qualitative approaches .........................63 Theme: Qualitative approaches/interviewing .............64 Theme: Qualitative
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]
  • Job Description and Person Specificationselection Criteria
    Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea.
    [Show full text]
  • Corporate Presentation
    Inducing T Cells to Treat and Prevent Disease Corporate Presentation August 2021 This presentation includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about our product development activities and clinical trials, our regulatory filings and approvals, our ability to develop and advance our current and future product candidates and programs, our ability to establish and maintain collaborations or strategic relationships or obtain additional funding, the rate and degree of market acceptance and clinical utility of our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates, our and our collaborators’ ability to protect our intellectual property for our products. By their nature, these statements are subject to numerous risks and uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance or events and circumstances described in the forward-looking statements will be achieved or occur.
    [Show full text]
  • Revised Register of Congregation Qualified Under the Provisions of Sect 3, Stat IV, of the Statutes of the University
    WEDNESDay 4 fEbruary 2015 • SuPPLEMENT (1) TO NO 5084 • VOL 145 Gazette Supplement Revised Register of Congregation Qualified under the provisions of Sect 3, Stat IV, of the Statutes of the University aarnio, O M, St Edmund Hall aldridge, H D J N, Development Office andrews, K S, Development Office aarts, D G a L, Christ Church aldridge, S, Queen's andrews, L a, research Services abate, a, Linacre aleksidze, N, Pembroke andrews, T M, faculty of Clinical Medicine abecassis, M, Wadham alen amaro, C M, Linacre andreyev, C C L, Christ Church abeler, J, St anne's alexander, C a H, Merton angel, a G, Dept of biochemistry aboobaker, a, Lady Margaret Hall alexander, J H, Linacre angelou, C L, Development Office abouzayd, S, Christ Church ali, H, faculty of Clinical Medicine angiolini, Dame Elish, St Hugh's abraham, D b, Wolfson ali, r, Cancer research uK Epidemiology unit angus, b J, NDM Experimental Medicine abrams, L J, balliol alkire, S M, Magdalen Division abramsky, S, Wolfson allan, C L, Wolfson anonuevo, E, finance Division acheson, D J, Jesus allan, J M, bodleian Enterprise units ansell, b W, Nuffield ackermann, S M, Linacre allan, J W, St Cross ansorge, O, Christ Church ackroyd, J M a, Social Sciences Division allan, W, university College anthony, D C, Somerville acuto, O, Lincoln allen, a M, Exeter antonini, M, St Peter's adam, a K M, St Stephen's House allen, C a, St Catherine's antoranz Contera, S, Green Templeton adam, C S, St Cross allen, G f, Pembroke aoki, y, Dept of Physiology, anatomy and adams, a C G, Merton allen, J M W, St
    [Show full text]
  • Title in Here, Arial 14 Bold, Caps
    News Release AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine Collaboration will enable global development, manufacturing and distribution of the vaccine 30 April 2020 AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV- 19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. This collaboration brings together the University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “The University of Oxford and AstraZeneca have a longstanding relationship to advance basic research and we are hugely excited to be working with them on advancing a vaccine to prevent COVID-19 around the world. We are looking forward to working with the University of Oxford and innovative companies such as Vaccitech, as part of our new partnership.” Alok Sharma, UK Business Secretary, said: “This collaboration between Oxford University and AstraZeneca is a vital step that could help rapidly advance the manufacture of a coronavirus vaccine.
    [Show full text]